Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
17.41
+0.15 (0.87%)
At close: Dec 5, 2025, 4:00 PM EST
17.07
-0.34 (-1.95%)
After-hours: Dec 5, 2025, 7:48 PM EST
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Monte Rosa Therapeutics stock ranges from a low of $13 to a high of $17. The average analyst price target of $15 forecasts a -13.84% decrease in the stock price over the next year.
Price Target: $15.00 (-13.84%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $10 → $13 | Hold | Maintains | $10 → $13 | -25.33% | Nov 7, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $11 → $10 | Hold | Maintains | $11 → $10 | -42.56% | Mar 21, 2025 |
| Wedbush | Wedbush | Buy Maintains $15 → $17 | Buy | Maintains | $15 → $17 | -2.35% | Mar 21, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $14 → $11 | Buy → Hold | Downgrades | $14 → $11 | -36.82% | Dec 19, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | -36.82% | Sep 12, 2024 |
Financial Forecast
Revenue This Year
137.27M
from 75.62M
Increased by 81.52%
Revenue Next Year
52.47M
from 137.27M
Decreased by -61.78%
EPS This Year
-0.29
from -0.98
EPS Next Year
-1.53
from -0.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 169.0M | 200.6M | ||||
| Avg | 137.3M | 52.5M | ||||
| Low | 105.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 123.4% | 46.1% | ||||
| Avg | 81.5% | -61.8% | ||||
| Low | 40.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.04 | -0.14 | ||||
| Avg | -0.29 | -1.53 | ||||
| Low | -0.43 | -1.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.